Dilpacimab - CAS 1791420-09-1

Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin that simultaneously targets the delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) signaling pathways. Dilpacimab has significant potential in cancer research due to its dual targeting of tumor angiogenesis and Notch signaling.

VEGFR, Gamma-secretase

Angiogenesis, Stem Cells, Neuroscience, Proteases/Proteasome, Tyrosine Kinase/Adaptors

1791420-09-1

0.977

-20°C

Ice Packs

Inhibitory Antibodies